Veracyte (VCYT) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Veracyte (NASDAQ: VCYT):

• 8/4/2026 – Veracyte had its price target lowered by Piper Sandler from $66.00 to $54.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Veracyte had its price target lowered by Stephens from $68.00 to $55.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Veracyte had its price target lowered by Morgan Stanley from $47.00 to $44.00. They now have an “underweight” rating on the stock.
• 8/3/2026 – Veracyte had its price target lowered by Canaccord Genuity Group Inc. from $60.00 to $50.00. They now have a “hold” rating on the stock.
• 7/31/2026 – Veracyte had its price target raised by Needham & Company LLC from $57.00 to $69.00. They now have a “buy” rating on the stock.
• 7/15/2026 – Veracyte is now covered by Piper Sandler. They set an “overweight” rating and a $66.00 price target on the stock.
• 7/15/2026 – Veracyte is now covered by Piper Sandler. They set an “overweight” rating and a $66.00 price target on the stock.
• 7/14/2026 – Veracyte had its price target raised by Canaccord Genuity Group Inc. from $42.00 to $60.00. They now have a “hold” rating on the stock.
• 7/13/2026 – Veracyte was downgraded by Zacks Research from “strong-buy” to “hold”.
• 7/12/2026 – Veracyte was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 7/9/2026 – Veracyte had its price target raised by Morgan Stanley from $37.00 to $47.00. They now have an “underweight” rating on the stock.
• 7/7/2026 – Veracyte was upgraded by Zacks Research from “hold” to “strong-buy”.
• 6/29/2026 – Veracyte had its price target raised by Guggenheim from $45.00 to $65.00. They now have a “buy” rating on the stock.
• 6/27/2026 – Veracyte was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/24/2026 – Veracyte had its “hold (c)” rating reaffirmed by Weiss Ratings.

Insiders Place Their Bets

In other Veracyte news, insider John Leite sold 13,975 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $50.07, for a total value of $699,728.25. Following the completion of the sale, the insider owned 132,305 shares in the company, valued at $6,624,511.35. This represents a 9.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Marc Stapley sold 138,051 shares of Veracyte stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.12, for a total transaction of $6,919,116.12. Following the sale, the chief executive officer directly owned 440,494 shares of the company’s stock, valued at $22,077,559.28. This trade represents a 23.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 196,492 shares of company stock valued at $9,680,897 over the last ninety days. Insiders own 1.60% of the company’s stock.

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.